Clavis Pharma ASA (OSL:CLAVIS) Oslo, Norway, 19 August 2008
Clavis Pharma ASA (CLAVIS) releases the company's second quarter 2008 results on Friday 22 August 2008. Geir Christian Melen, CEO, will present the second quarter results from 08:30 CET at:
Hotel Continental Stortingsgaten 24/26 0112 Oslo
Following the presentation, there will be a Q&A session. Breakfast will be served from 08:00 CET
Clavis Pharma welcomes all interested parties.
The quarterly report and quarterly presentation will be available at the Oslo Stock Exchange, http://www.newsweb.no and Clavis Pharma's homepage, http://www.clavispharma.com
Contacts: Geir Christian Melen, CEO Office : +47 24 11 09 65 Mobile : +47 91 30 29 65 E-mail : geir.christian.melen@clavispharma.com
Gunnar Manum, CFO Office : +47 24 11 09 71 Mobile : +47 95 17 91 90 E-mail : gunnar.manum@clavispharma.com
About Clavis Pharma Clavis Pharma ASA is an oncology focused pharmaceutical company using its proprietary Lipid Vector Technology (LVT) platform to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration and, in many cases, additional modes of action. Clavis Pharma's objective is to develop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter into strategic partnerships with established pharmaceutical or biotech companies. The company's product portfolio includes three new cancer drugs, of which the first ELACYT(TM) , is in Clinical Phase II, the second, CP-4126, is in Clinical Phase I, and the third, CP-4200, is in Preclinical Development. Results indicate that these products have promising potential for several cancer indications within solid tumours and leukaemia. The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange, with the ticker CLAVIS. Additional information can be found at: www.clavispharma.com.
Clavis Pharma ASA
http://www.clavispharma.com
ISIN: NO0010308240
Stock Identifier: XOSL.CLAVIS
Clavis Pharma ASA (CLAVIS) releases the company's second quarter 2008 results on Friday 22 August 2008. Geir Christian Melen, CEO, will present the second quarter results from 08:30 CET at:
Hotel Continental Stortingsgaten 24/26 0112 Oslo
Following the presentation, there will be a Q&A session. Breakfast will be served from 08:00 CET
Clavis Pharma welcomes all interested parties.
The quarterly report and quarterly presentation will be available at the Oslo Stock Exchange, http://www.newsweb.no and Clavis Pharma's homepage, http://www.clavispharma.com
Contacts: Geir Christian Melen, CEO Office : +47 24 11 09 65 Mobile : +47 91 30 29 65 E-mail : geir.christian.melen@clavispharma.com
Gunnar Manum, CFO Office : +47 24 11 09 71 Mobile : +47 95 17 91 90 E-mail : gunnar.manum@clavispharma.com
About Clavis Pharma Clavis Pharma ASA is an oncology focused pharmaceutical company using its proprietary Lipid Vector Technology (LVT) platform to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration and, in many cases, additional modes of action. Clavis Pharma's objective is to develop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter into strategic partnerships with established pharmaceutical or biotech companies. The company's product portfolio includes three new cancer drugs, of which the first ELACYT(TM) , is in Clinical Phase II, the second, CP-4126, is in Clinical Phase I, and the third, CP-4200, is in Preclinical Development. Results indicate that these products have promising potential for several cancer indications within solid tumours and leukaemia. The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange, with the ticker CLAVIS. Additional information can be found at: www.clavispharma.com.
Clavis Pharma ASA
http://www.clavispharma.com
ISIN: NO0010308240
Stock Identifier: XOSL.CLAVIS
| Tweet |
 |
Related Companies |
>>> Clavis Pharma ASA |
| |
Related Industry Topics: |
European Finance News | |
| |
This Page Viewed: (Last 7 Days: 10) (Last 30 Days: 40) (Since Published: 2830) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
